Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Project did not receive final IRB approvals. PI decided to withdrawn research study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The overall project goal is to conduct a pilot randomized clinical trial of operative (laparoscopic appendectomy) vs nonoperative (antibiotic) management of uncomplicated acute appendicitis for vulnerable populations. Specifically, the elderly, non-English speakers, and those with economic vulnerability (low socioeconomic status and/or manual labor jobs without a non-weight lifting aspect), are three vulnerable population subsets identified. This pilot trial will provide critical preliminary data for planning and conducting a larger multi-site randomized trial.
The study would involve consented subjects, once confirmed eligible to proceed after screening, will be randomly assigned to two arms:
Aside from the routine hospital care, participants will be asked to fill out a survey for cognitive function (CAM Assessment Form), pain (Visual Analog Scale), and quality of life at the start and end of participant's hospital stay, 1-2 weeks after discharge, and again at 6 weeks after discharge from the initial hospital visit.
Participants will also be asked to participate in a qualitative interview, either by virtual visit, site visit, or phone call, at 1-2 weeks and again at about 6 weeks after discharge from the hospital. Each interview will be approximately 20-30 minutes of the participant's time.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Operative Arm | Experimental | Operation (laparoscopic appendectomy) will be performed to remove appendix. |
|
| Non-Operative Arm | Experimental | No operation will be performed, and instead, will receive intra-venous (IV) antibiotics, transitioned to by mouth (oral) antibiotics |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Laparoscopic appendectomy | Procedure | Subjects will receive surgery (using 3 port Laparoscopic appendectomy) to remove appendix |
|
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility of the intervention as measured by the proportion of enrolled participants retained in this study | Feasibility of the intervention is measured by the proportion of enrolled participants who are randomized and retained in this study | 12 months post treatment |
| Feasibility of the intervention as measured by the number of complications or adverse events | Feasibility of the intervention is measured by the number of complications or adverse events encountered by participants while enrolled in this study | 12 months post treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility of the intervention as measured by total length of hospital stay (Antibiotics Group) | Feasibility of the intervention is measured by total number of days in inpatient hospital stay for the IV antibiotics group post treatment | the day of discharge (approx. 1-3 days post treatment) |
| Feasibility of the intervention as measured by total length of hospital stay (Operative Group) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sneha Bhat | University of Texas Southwestern Medical Center | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001064 | Appendicitis |
| ID | Term |
|---|---|
| D059413 | Intraabdominal Infections |
| D007239 | Infections |
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000900 | Anti-Bacterial Agents |
| ID | Term |
|---|---|
| D000890 | Anti-Infective Agents |
| D045506 | Therapeutic Uses |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Antibiotics (IV transitioned to oral) | Drug | Subjects will be admitted to the hospital for antibiotic treatment, initially with IV antibiotics and then transitioned to by mouth (PO) antibiotics for the rest of the course. Drugs used would be anything from: zosyn, ciprofloxacin or ceftriaxone and flagyl, augmentin |
|
Feasibility of the intervention is measured by total number of days in inpatient hospital stay for the Operative group post laparoscopic appendectomy |
| the day of discharge (approx. 0-2 days post treatment) |
| Feasibility of the intervention as measured by the number of hospital readmissions or emergency room visits | Feasibility of the intervention is measured by the count of the number of hospital readmissions or emergency room visits by the participants at 1-2 weeks post-discharge | 1-2 weeks post-discharge |
| Feasibility of the intervention as measured by the number of hospital readmissions or emergency room visits | Feasibility of the intervention is measured by the count of the number of hospital readmissions or emergency room visits by the participants at 6 weeks post-discharge | 6 weeks post-discharge |
| Feasibility of the intervention as measured by QoL surveys | Feasibility of the intervention is measured by administering Quality of Life (QoL) surveys using Quality of Recovery-40 questionnaire. This is a self-rated questionnaire for early postoperative quality of recovery and health status of patients. Possible scores range from 1 to 5, where higher scores indicate better quality of life (i.e., 1 = very poor and 5 = excellent) | prior to discharge home (approx. 4-6 hours post treatment) |
| Feasibility of the intervention as measured by QoL surveys | Feasibility of the intervention is measured by administering Quality of Life (QoL) surveys using Quality of Recovery-40 questionnaire. This is a self-rated questionnaire for early postoperative quality of recovery and health status of patients. Possible scores range from 1 to 5, where higher scores indicate better quality of life (i.e., 1 = very poor and 5 = excellent) | 1-2 weeks post-discharge |
| Feasibility of the intervention as measured by QoL surveys | Feasibility of the intervention is measured by administering Quality of Life (QoL) surveys using Quality of Recovery-40 questionnaire. This is a self-rated questionnaire for early postoperative quality of recovery and health status of patients. Possible scores range from 1 to 5, where higher scores indicate better quality of life (i.e., 1 = very poor and 5 = excellent) | 6 weeks post-discharge |
| Change in pain score from baseline as measured by visual analog pain scale at prior to discharge home (approx. 4-6 hours post treatment) | Change in pain score from baseline is measured by visual analog pain scale at prior to discharge home (approx. 4-6 hours post treatment). Possible scores range from 0-10, where 0= no pain and 10= worst pain. | Baseline, prior to discharge home (approx. 4-6 hours post treatment) |
| Change in pain score from baseline as measured by visual analog pain scale at 1-2 weeks post discharge | Change in pain score from baseline is measured by visual analog pain scale at weeks post discharge. Possible scores range from 0-10, where 0= no pain and 10= worst pain. | Baseline, 1-2 weeks post discharge |
| Change in pain score from baseline as measured by visual analog pain scale at 6 weeks post discharge | Change in pain score from baseline is measured by visual analog pain scale at 6 weeks post discharge. Possible scores range from 0-10, where 0= no pain and 10= worst pain. | Baseline, 6 weeks post discharge |
| Change in cognitive function as measured by CAM assessment form at 1-2 weeks post discharge | Change in cognitive function is measured by Short Confusion Assessment Method (CAM) Questionnaire at 1-2 weeks post discharge. If Inattention and at least one other item ( regarding acute change in mental status; inattention) in Box 1 of the questionnaire are checked and at least one item (regarding disorganized thinking; altered level of consciousness) in Box 2 of the questionnaire is checked, then a diagnosis of delirium is suggested. | Baseline, 1-2 weeks post discharge |
| Change in cognitive function as measured by CAM assessment form at 6 weeks post discharge | Change in cognitive function is measured by Short Confusion Assessment Method (CAM) Questionnaire at 6 weeks post discharge. If Inattention and at least one other item ( regarding acute change in mental status; inattention) in Box 1 of the questionnaire are checked and at least one item (regarding disorganized thinking; altered level of consciousness) in Box 2 of the questionnaire is checked, then a diagnosis of delirium is suggested. | Baseline, 6 weeks post discharge |
| Feasibility of the intervention as measured by physical function using FRAIL scale | Feasibility of the intervention is measured by physical function using FRAIL scale. The Fatigue Resistance Ambulation Illness and Loss of weight (FRAIL) scale includes 5 components: Fatigue, Resistance, Ambulation, Illness, and Loss of weight. Frail scale scores range from 0-5 (i.e., 1 point for each component; 0=best to 5=worst) and represent frail (3-5), pre-frail (1-2), and robust (0) health status. | Baseline |
| Feasibility of the intervention as measured by hospital costs for each enrolled participant (Antibiotics Group) | Feasibility of the intervention is measured by accessing billing codes/hospital costs for each enrolled subject from the time they are admitted until they are discharged from the hospital. | the day of discharge (approx. 1-3 days post treatment) |
| Feasibility of the intervention as measured by hospital costs for each enrolled participant (Operative Group) | Feasibility of the intervention is measured by accessing billing codes/hospital costs for each enrolled subject from the time they are admitted until they are discharged from the hospital. | the day of discharge (approx. 0-2 days post treatment) |
| D004066 |
| Digestive System Diseases |
| D002429 | Cecal Diseases |
| D007410 | Intestinal Diseases |